Introduction: BHIVA guidelines recommend screening HIV positive individuals for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV) at diagnosis and annually thereafter for those who are not infected or immune. We investigated adherence to these guidelines. Methods: UK CHIC is an on-going observational study of individuals attending for care at selected HIV centres. Individuals attending any of 11 centres from 2004 onwards were included. Logistic regression identiﬁed predictors of ever testing for HBsAg or anti-HCV. Patients were eligible for annual testing if at the start of each year if they had no prior evidence of HBsAg, immunity to hepatitis B or anti-HCV. Results: Of 31,605 individuals, 26,157 (82.8%) had a HBsAg test result recorded and 27,894 (88.3%) had an anti-HCV result. CD4, viral load, calendar year, ethnicity and exposure were all associated with testing (Table1). The proportion of patients tested increased from 2004 to 2011 (HBsAg, 54.3% -88.3% and anti-HCV, 57.4%-94.1%). For both HBsAg and anti-HCV, a signiﬁcant interaction between calendar year and exposure was identiﬁed with the increase in testing among men who have sex with men (MSM) being greater than the increase in any other exposure group (p<0.0001 for HBsAg and anti-HCV models, results not shown). Annual testing of eligible individuals increased from 20.5% in 2004 to 29.7% in 2011 for HBsAg and from 25.6% to 55.7% for anti-HCV. Conclusion: Most HIV positive individuals are now screened for hepatitis B and C at least once. There is evidence of increasing testing over time especially among MSM. Despite a modest increase in the proportion of eligible patients who are tested each year, annual testing remains low.
|Number of pages||2|
|Publication status||Published - 26 Jun 2014|
- Science & Technology
- Life Sciences & Biomedicine
- Infectious Diseases